Overview
Using 23andMe’s 2025 Chapter 11 sale to TTAM Research Institute, this series separates saliva samples, genetic results, account records, customer rights, and the operating business; traces the Equity Toggle, custody, access, consent, and privacy-law analysis; and follows post-closing controls and state enforcement. It shows why approval was transaction-specific and did not make genetic data an unrestricted asset.
Learning outcomes
- The 23andMe estate could transfer business-held interests without automatically transferring customers’ property and control rights.
- The Equity Toggle changed legal custody and corporate control, while existing access and the testing purpose were expected to continue.
- Bankruptcy authorized the sale process but did not create a blanket exemption from state privacy law or consent rules.
- Deletion, research opt-out, governance, and enforcement provided accountability, but the court did not guarantee future security or access.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
Can bankruptcy sell 23andMe genetic data?
Yes, but only in the limited sense that the estate could transfer its business-held interests; customer rights and privacy-law limits remained.
What did the 23andMe Equity Toggle transfer?
It transferred the debtors’ business-held interests into Newco, then transferred Newco’s equity to TTAM. That changed custody and corporate control without necessarily changing the access group.
Did 23andMe customers need new consent for the sale?
On the facts before the court, no separate express consent was required under the state statutes at issue because the business, access group, and purpose were expected to continue.
What protections remained after the 23andMe sale?
The terms preserved account and data deletion and research opt-out rights, required applicable-law compliance, and added governance and transaction limits, but did not guarantee future security.